April 27, 2020
AbbVie rolled out its oral JAK inhibitor Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis (RA) that is inadequately controlled with existing treatments on April 24, two days after its reimbursement listing with a peak sales outlook of 28.3 billion...read more